Different safety profiles of first-line bendamustine-rituximab (BR), R-CHOP, and R-CVP in an open-label, randomized study of indolent non-Hodgkin lymphoma (NHL) and mantle cell lymphoma (MCL): The BRIGHT study

被引：0

作者：

MacDonald, David

van der Jagt, Richard

Burke, John M.

Kahl, Brad S.

Wood, Peter

Hawkins, Tim E.

Hertzberg, Mark

Kwan, Yiu-Lam

Simpson, David

Craig, Michael

Kolibaba, Kathryn S.

Issa, Samar

Clementi, Regina

Hallman, Doreen M.

Munteanu, Mihaela C.

Chen, Ling

Flinn, Ian

机构：

[1] Dalhousie Univ, Halifax, NS, Canada

[2] Univ Ottawa, Ottawa, ON, Canada

[3] Rocky Mt Canc Ctr, Aurora, CO USA

[4] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA

[5] Princess Alexandra Hosp, Woolloongabba, Qld 4102, Australia

[6] Auckland Hosp, Auckland, New Zealand

[7] Westmead Hosp, Wentworthville, Australia

[8] Concord Repatriat Gen Hosp, Concord West, NSW, Australia

[9] North Shore Hosp, Takapuna, New Zealand

[10] W Virginia Univ, Morgantown, WV 26506 USA

[11] Compass Oncol, Vancouver, WA USA

[12] Middlemore Hosp, Auckland 6, New Zealand

[13] Teva Pharmaceut Inc, Frazer, PA USA

[14] Sarah Cannon Res Inst, Nashville, TN USA

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

8565

引用

页数：1